YatinVyasMDMBBS

Pediatric Hematology & Oncology • Hershey, PA

Chair of Pediatrics, Penn State Health Milton S. Hershey Medical Center

Join to view full profile

Dr. Vyas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vyas' full profile

Already have an account?

Office
600 University Dr
Hershey, PA 17033
Phone+1 717-531-6012

Fax+1 717-531-4789

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1995 - 1998
NYU Grossman School of MedicineResidency, Pediatrics, 1993 - 1995
B. J. Medical College AhmedabadClass of 1987

Certifications & Licensure

PA State Medical License 2005 - 2024
IA State Medical License 2013 - 2023
NJ State Medical License 1999 - 2005
NY State Medical License 2002 - 2005
American Board of Pediatrics Pediatric Hematology-Oncology

Publications & Presentations

PubMed

255 citations
Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
Ekaterina Doubrovina, Mikhail Doubrovin, Elena Vider, Richard B. Sisson, Richard J. O'Reilly
Journal of Immunology. 2003-12-15
25 citations
SUMOylation-disrupting WAS mutation converts WASp from a transcriptional activator to a repressor of NF-κB response genes in T cells
Koustav Sarkar, Sanjoy Sadhukhan, Seong-Su Han, Yatin M. Vyas
Blood. 2015-10-01
34 citations
R-loops cause genomic instability in T helper lymphocytes from patients with Wiskott-Aldrich syndrome
Koustav Sarkar, Seong-Su Han, Kuo Kuang Wen, Hans D. Ochs, Loïc Dupré
The Journal of Allergy and Clinical Immunology. 2018-07-01

Press Mentions

$Senhwa Biosciences Announces First Patient Dosed in the Phase I/II Study of Silmitasertib in Children and Young Adults with Relapsed Refractory Solid Tumors$
Senhwa Biosciences Announces First Patient Dosed in the Phase I/II Study of Silmitasertib in Children and Young Adults with Relapsed Refractory Solid TumorsNovember 6th, 2024
Penn State Health Children’s Hospital Ranks Among Nation's Best in Two SpecialtiesOctober 8th, 2024
Penn State Health Children’s Hospital Ranks Among Best in NationOctober 8th, 2024
Join now to see all